Assessing Potential Impact of a Farmer Field School Training on Perennial Crop in Cameroon

This study is an attempt of the combination of multiple data sources referring to the same time period and to the same farmer population, it aims at assessing the potential impact of a cocoa Farmer Field School Training on Integrated Pest Management in Cameroon. Using a combination of a latitudinal and a longitudinal comparison, the results indicate that FFS-trained farmers have significantly more knowledge about crop husbandry practices than those in the non-participant comparison group. A 32% production increase and 45% income increase relative to the non-participants was estimated in the latitudinal analysis. The longitudinal comparison is showing significant adoption rates of 94, 93, 90, 66 and 35 % respectively for shade management, phytosanitary harvest, pruning, improved spraying practices and grafting of improved materials. There was a 47 % reduction in the frequency of spraying fungicides and a 17 % reduction in the number of sprayers applied per treatment following the implementation of the training. Labour inputs increased significantly for pruning, phytosanitary harvest, and shade management but decreased for spraying. A partial budget analysis reveals that the IPM practices lowered overall costs of production by 11 % relative to previous practices. The two different analytical tools (longitudinal and latitudinal) are convergent in their results, showing more evidence about the higher potential impact of the farmer field school training on the restructuring process of the cocoa sector in Cameroonintegrated pest management, farmer field school, adoption rate, Agricultural and Food Policy, Community/Rural/Urban Development, Demand and Price Analysis, Environmental Economics and Policy, Farm Management, Food Consumption/Nutrition/Food Safety, Food Security and Poverty, Land Economics/Use, Marketing, Research and Development/Tech Change/Emerging Technologies,

Truncation of gene F5L partially masks rescue of vaccinia virus strain MVA growth on mammalian cells by restricting plaque size

Modified vaccinia virus Ankara (MVA) is a candidate vaccine vector that is severely attenuated due to mutations acquired during several hundred rounds of serial passage in vitro. A previous study used marker rescue to produce a set of MVA recombinants with improved replication on mammalian cells. Here, we extended the characterization of these rescued MVA strains and identified vaccinia virus (VACV) gene F5L as a determinant of plaque morphology but not replication in vitro. F5 joins a growing group of VACV proteins that influence plaque formation more strongly than virus replication and which are disrupted in MVA. These defective genes in MVA confound the interpretation of marker rescue experiments designed to map mutations responsible for the attenuation of this important VACV strain.This work was funded by grants to DCT: NHMRC APP1023141 and ARC FT110100310

Mach number distribution on blade to blade surface of a turbine stator pasage

Mach number distribution on the blade to blade surface l was computed at the hub, mean and tip sections of a stator' blade using the computer program COMPBLADE. These results,; were used to plot i so-Mach contours on the blade to blade surface and surface velocity distribution as a function- of fractional surface length. The results have been presented`' in this report

Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system

Human endogenous retrovirus (HERV) genomes are chromosomally integrated in all cells of an individual. They are normally transcriptionally silenced and transmitted only vertically. Enhanced expression of HERV-K accompanied by the emergence of anti-HERV-K-directed immune responses has been observed in tumor patients and HIV-infected individuals. As HERV-K is usually not expressed and immunological tolerance development is unlikely, it is an appropriate target for the development of immunotherapies. We generated a recombinant vaccinia virus (MVA-HKenv) expressing the HERV-K envelope glycoprotein (ENV), based on the modified vaccinia virus Ankara (MVA), and established an animal model to test its vaccination efficacy. Murine renal carcinoma cells (Renca) were genetically altered to express E. coli beta-galactosidase (RLZ cells) or the HERV-K ENV gene (RLZ-HKenv cells). Intravenous injection of RLZ-HKenv cells into syngenic BALB/c mice led to the formation of pulmonary metastases, which were detectable by X-gal staining. A single vaccination of tumor-bearing mice with MVA-HKenv drastically reduced the number of pulmonary RLZ-HKenv tumor nodules compared to vaccination with wild-type MVA. Prophylactic vaccination of mice with MVA-HKenv precluded the formation of RLZ-HKenv tumor nodules, whereas wild-type MVA-vaccinated animals succumbed to metastasis. Protection from tumor formation correlated with enhanced HERV-K ENV-specific killing activity of splenocytes. These data demonstrate for the first time that HERV-K ENV is a useful target for vaccine development and might offer new treatment opportunities for diverse types of cancer

The MVA Priority Approximation

A Mean Value Analysis (MVA) approximation is presented for computing the average performance measures of closed-, open-, and mixed-type multiclass queuing networks containing Preemptive Resume (PR) and nonpreemptive Head-Of-Line (HOL) priority service centers. The approximation has essentially the same storage and computational requirements as MVA, thus allowing computationally efficient solutions of large priority queuing networks. The accuracy of the MVA approximation is systematically investigated and presented. It is shown that the approximation can compute the average performance measures of priority networks to within an accuracy of 5 percent for a large range of network parameter values. Accuracy of the method is shown to be superior to that of Sevcik's shadow approximation

The Analysis of Financial Performance Using Economic Value Added (Eva) and Market Value Added (Mva) Methods and Its Influence on Stock Return of Transportation Company Listed in Indonesia Stock Exchange

This study was conducted to examine the effect of Economic Value Added (EVA) and Market Value Added (MVA) and Its Effect on Stock Return. The research sample was taken from 5 transport company listed on the Indonesia Stock Exchange that have been through the process in accordance with the criteria of sample or random sampling method. Data analysis methods used in the study panel data analysis method using Eviews program. Results showed partial EVA has no real effect, with significant values of 0.2661, while MVA and significant influence on Return Stocks with significant value of 0.0463 as indicated by the results of the test statistic t. While simultaneously or jointly Economic Value Added (EVA) and Market Value Added (MVA) influence on Stock Return, this is evidenced by the results of the test statistic f the significant value of 0.038

EMDR therapy for PTSD after motor vehicle accidents: meta-analytic evidence for specific treatment

Motor vehicle accident (MVA) victims may suffer both acute and post-traumatic stress disorders (PTSD). With PTSD affecting social, interpersonal and occupational functioning, clinicians as well as the National Institute of Health are very interested in identifying the most effective psychological treatment to reduce PTSD. From research findings, eye movement desensitization and reprocessing (EMDR) therapy is considered as one of the effective treatment of PTSD. In this paper, we present the results of a meta-analysis of fMRI studies on PTSD after MVA through activation likelihood estimation. We found that PTSD following MVA is characterized by neural modifications in the anterior cingulate cortex (ACC), a cerebral structure involved in fear-conditioning mechanisms. Basing on previous findings in both humans and animals, which demonstrate that desensitization techniques and extinction protocols act on the limbic system, the effectiveness of EMDR and of cognitive behavioral therapies (CBT) may be related to the fact that during these therapies the ACC is stimulated by desensitization

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

<div><p>Background</p><p>Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral immunogenic equivalence of three consecutively manufactured MVA production lots, and to confirm the safety and tolerability of MVA focusing on cardiac readouts.</p><p>Methods</p><p>The trial was conducted at 34 sites in the US. Vaccinia-naïve adults aged 18-40 years were randomly allocated to one of four groups using a 1:1:1:1 randomization scheme. Subjects received either two MVA injections from three consecutive lots (Groups 1-3), or two placebo injections (Group 4), four weeks apart. Everyone except personnel involved in vaccine handling and administration was blinded to treatment. Safety assessment focused on cardiac monitoring throughout the trial. Vaccinia-specific antibody titers were measured using a Plaque Reduction Neutralization Test (PRNT) and an Enzyme-Linked Immunosorbent Assay (ELISA). The primary immunogenicity endpoint was Geometric Mean Titers (GMTs) after two MVA vaccinations measured by PRNT at trial visit 4. This trial is registered with ClinicalTrials.gov, number NCT01144637.</p><p>Results</p><p>Between March 2013 and May 2014, 4005 subjects were enrolled and received at least one injection of MVA (n = 3003) or placebo (n = 1002). The three MVA lots induced equivalent antibody titers two weeks after the second vaccination, with seroconversion rates of 99·8% (PRNT) and 99·7% (ELISA). Overall, 180 (6·0%) subjects receiving MVA and 29 (2·9%) subjects in the placebo group reported at least one unsolicited Adverse Event (AE) that was considered trial-related. Vaccination was well tolerated without significant safety concerns, particularly regarding cardiac assessment.</p><p>Conclusions</p><p>The neutralizing and total antibody titers induced by each of the three lots were equivalent. No significant safety concerns emerged in this healthy trial population, especially regarding cardiac safety, thus confirming the excellent safety and tolerability profile of MVA.</p><p>Trial registration</p><p>ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT01144637" target="_blank">NCT01144637</a></p></div